BCL2 and glioma: High-grade gliomas have a higher WT1 expression level compared with low-grade gliomas [20], and BCL2 is associated with the higher tumour grades, poorer patient survival, and the conferring of treatment resistance through its own action and the action of other gene family members [21-25].